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PCV23
HEALTH CARE AND DRUG UTILIZATION PATTERNS IN
PATIENTS RECEIVING LONG TERM THIENOPYRIDINE
THERAPY
McCollam PL1, Lage M2, Bowman L1
1Eli Lilly and Company, Indianapolis, IN, USA; 2HealthMetrics
Outcomes Research, Groton, CT, USA
OBJECTIVES: Long-term antiplatelet therapy is typically con-
sidered standard of care for secondary prevention of cardiac
events. The goal of this study was to examine patterns of use
and total health care utilization in patients receiving clopidogrel.
METHODS: The study used a random subset of the Pharmet-
rics Patient-Centric Database (2001–2002) representing 3
million commercially insured members. Inclusion criteria were:
index prescription for clopidogrel preceded by a 3-month drug
free pre-period, followed by a 6-month post-period. RESULTS:
Of 11,000 patients included; mean age was 63.7, 58% were
male, 74% were Health Maintenance Organization members.
Common comorbidities included: diabetes 24%, myocardial
infarction 16%, acute coronary syndrome 18%, angina 18%,
coronary heart disease 57%, stroke/transient ischemic attack
24%. Pre-period resource utilization showed 33% had an 
Emergency Room (ER) encounter, 58% were hospitalized, 58%
had a cardiologist encounter, 38% a general practitioner (GP)
encounter. Mean total charges were $25,807. Percutaneous coro-
nary intervention (PCI) was also common (38.6%). In the post-
period, 24% had an ER encounter, 54% were hospitalized, 44%
had a cardiologist encounter, 63% a GP encounter. Mean total
charges were $17,357. PCI occurred in 8.4% during the post-
period. Sixty-seven percent of patients received the index clopi-
dogrel prescription within 7 days of an ER encounter. Mean
length of clopidogrel therapy was 86 days. Patterns of use
showed 67% Stopped (not on clopidogrel 28-days prior to end
of follow-up), 82% with a Gap (reﬁlls were > 14 days apart).
Concomitant statin use occurred in 57% (atorvastatin 32%).
CONCLUSIONS: As deﬁned by an index prescription, substan-
tial resources were used both pre and post-period and coronary
intervention was common. Long-term adherence to clopidogrel
was poor and did not meet current guidelines. Patients receiving
clopidogrel had many comorbidities and were high utilizers of
health care resources, suggesting the need for better guideline
compliance and perhaps better treatments.
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7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS
WITH ESSENTIAL HYPERTENSION
Nair RR, Bollu VK, Blake SG
The University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVE: About 30% of US adult population suffers from
hypertension and this rate is expected to increase in coming
years. This study examined current therapeutic choices associ-
ated with treatment of essential hypertension. Hypertensive
related and total health care resource utilization were also exam-
ined. METHODS: Data from 2000 Medical Expenditure Panel
Survey were retrospectively analyzed. Patients were identiﬁed by
the ICD-9 CM code “401”, who were above 17 years of age and
were not pregnant. All patients who received an anti-hyperten-
sive also had a diagnosis of essential hypertension. Health care
resource utilization was measured from ER, inpatient, physician,
and prescription medicine expenses. RESULTS: A total of 2894
patients were identiﬁed as diagnosed with essential hypertension.
Patients in the study group were predominantly female (58%),
caucasians (78%), and over 50 years of age (75%). Angiotensin
Converting Enzyme inhibitors (ACE) and Calcium Channel
Blockers (CCB) formed the major treatment choices for essential
hypertension. The choice of treatment strategy differed with
patient’s type of insurance. Only 25% of study group rated their
general health as excellent or very good (SF–12). About 8% of
the study population had at least one episode of stroke. Total
health care expenses for the study group exceeded $15 million.
The mean total health care expense for a single hypertensive
patient was above $5000. Prescription anti-hypertensives were
23% of the total health care expenses. Physician and ER visits
were found to be the major cost categories for the hypertension
patients. CONCLUSIONS: Health care resource utilization by
hypertensive patients is expected to increase with the increase in
the number of patients. CCBs and ACE inhibitors formed the
treatment of choice for hypertension treatment. Prescription
medicine expenses formed only a small percentage of the total
health care expense.
PCV25
TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER:
IS THE SHORT TERM LONG OVERDUE?
Reed KE,Wieck SG, Tengs TO
Milliman USA, Denver, CO, USA
OBJECTIVE: Despite overwhelming evidence that tobacco ces-
sation interventions are cost-effective, only 24% of employer-
sponsored health plans offer any coverage for tobacco-use
treatment. One reason may be that health plans fear that they
won’t recoup projected savings because of member turnover,
which averages 10–20% annually. The objective of this study
was to assess whether the cost-effectiveness literature provides
health plans with the information they need to make tobacco
treatment coverage decisions. METHODS: We performed a com-
prehensive search for all cost-effectiveness analyses of tobacco
cessation interventions published in 1980 or later. Two readers
independently reviewed 23 analyses and recorded several items
including: 1) the perspective of the analysis; 2) whether medical
cost savings were assessed; 3) the time-frame over which the
medical costs were calculated; and 4) whether comprehensive
program implementation costs were included. RESULTS: Of the
23 analyses reviewed, 13 described the cost-effectiveness of
potentially reimbursable services or medications from the payer’s
perspective. However, of the 13, only two incorporated medical
cost offsets from smoking cessation. Neither described the cost
implications over the short term nor did they include the
program costs that are of interest to payers. CONCLUSIONS:
Published cost-effectiveness information for tobacco treatments
is not presented in a way that is useful to health plans. Provid-
ing information in a manner more useful to managed care orga-
nizations, emphasizing short term cost savings, could lead to
better coverage of tobacco treatment.
PCV26
MEDICARE EXPENDITURES IN RELATION TO FUNCTIONAL
HEALTH STATUS POST-STROKE FOR A NATIONALLY-
REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES
FROM 1996 TO 2000
Singhal PK, Stuart B, Menis M, Kamal-Bahl S
University of Maryland, Baltimore, MD, USA
OBJECTIVES: 1) Using Medicare Current Beneﬁciary Survey
(MCBS) develop a retrospective cohort of Medicare beneﬁciaries
with incident stroke; and 2) determine Medicare expenditures in
relation to health status and time since stroke. METHODS: We
used longitudinal MCBS surveys linked to Medicare claims from
1996 to 2000. The MCBS reports data from in-home interviews
on a nationally-representative sample of approximately 17,000
Medicare beneﬁciaries each year. It contains detailed information
on beneﬁciaries’ socio-demographic characteristics and general
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health and functioning, and is limited to Medicare claims. For
each year of MCBS sample, individuals with incident stroke were
identiﬁed from primary or secondary diagnoses on inpatient
claims records using ICD-9 codes 433, 434, 436, and 437. Fol-
lowing stroke, three measures of health status including general
health, activities of daily living (ADL), and instrumental activi-
ties of daily living (IADL) were determined and indexed to the
stroke date. Medicare expenditures for all health care services
during the same period as health assessments were determined
from billing records and indexed. Severity measures including co-
morbidities, length of hospital stay, and nursing-home admis-
sions were determined from billing records. Analyses included
descriptive statistics and bivariate analyses using t-tests and chi-
square with signiﬁcance level of 0.05. RESULTS: We identiﬁed
1125 beneﬁciaries with an incident stroke. Lower levels of health
on all three measures of health status were associated with higher
mean (SD) expenditures: $6756 ($1432) for fair to poor health
compared to $2759 ($6500) for good to excellent health; $6519
($11,373) for 3 or more ADL limitations compared to $3899
($13,782) for less limitations; and $5988 ($9019) for 3 or more
IADL limitations compared to $4774 ($13,413) for less limita-
tions. Overall, expenditures showed declining trends post-stroke.
CONCLUSION: Preliminary ﬁndings suggest that health status
and time since stroke affect expenditures. Multivariate analyses
using generalized estimating equations will be conducted to
conﬁrm these ﬁndings.
PCV27
HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-
MI PATIENTS WITH HEART FAILURE
Arondekar BV1, Basu A2,Walton SM1,Akhras K3
1University of Illinois at Chicago, Chicago, IL, USA; 2University of
Chicago, Chicago, IL, USA; 3Pﬁzer Inc, Skokie, IL, USA
OBJECTIVES: Clinical trials indicate that the development of
heart failure (HF) impacts post-myocardial infarction (MI) prog-
nosis. There is little information available on the economic
burden of HF in post-MI patients, outside of a clinical trial
setting. This study examines and compares the impact of devel-
oping HF on cost of care and length of stay (LOS) in patients
hospitalized for MI using alternative models for estimation.
METHODS: Claims data for patients hospitalized with a prin-
cipal diagnosis of MI between 1998 and 2000 were used to
compare cost of care and LOS between those with and without
HF at initial hospitalization. Patients with a diagnosis of HF in
the 6-months preceding the MI were excluded. Total hospital-
ization costs and LOS were analyzed for 15,160 patients using
OLS, log-OLS and generalized linear models (GLM). Bootstrap-
ping was used to obtain variances for cost estimates. Age, gender,
type of MI, death, Medicare/non-Medicare, and comorbidities
were included as covariates in the models. RESULTS: Compar-
ing post-MI patients who develop HF during initial hospitaliza-
tion (N = 2968) to those without HF at initial hospitalization (N
= 12,192) the mean incremental cost and incremental LOS were
$7098 (SD = $434), and 3 days (SD = 0.13) respectively using
the GLM. Based on several diagnostic tests, GLM was found to
be the best estimator as long as the link function used is appro-
priate. Log-OLS estimates were biased both due to het-
eroscedasticity and the inappropriateness of log-transformation.
OLS estimates were both biased and inefﬁcient especially for
costs. CONCLUSIONS: Patients who develop post-MI HF
during initial hospitalization for MI have signiﬁcantly higher
hospitalization costs and increased LOS as compared to patients
without post-MI HF. Treatments aimed at preventing or delay-
ing the onset of post-MI HF could result in signiﬁcant cost
savings.
PCV28
AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-
TO-MODERATE HYPERTENSION
Smolen HJ1, Klein RW1, Ohsfeldt RL2, Poret AW3,Weinberger MH4
1Medical Decision Modeling Inc, Indianapolis, IN, USA; 2University of
Iowa, Iowa City, IA, USA; 3Boehringer Ingelheim Pharmaceuticals, Inc.,
Ingelheim, Germany; 4Indiana University, Indianapolis, IN, USA
OBJECTIVE: The model compares—from a health system’s 
perspective—the cardiovascular events avoided and costs of six
angiotensin receptor blockers (ARBs) in treating mildly-to-
moderately hypertensive patients. METHODS: The model con-
siders three potential differences in effectiveness among ARBs:
1) ofﬁce cuff systolic blood pressure (SBP) reduction; 2) 24-hour
ambulatory systolic blood pressure (ABP), and 3) non-compli-
ance. The model uses point estimates of SBP reductions from
published trials and meta-analyses identiﬁed from Medline and
searches of retrieved literature published after 1996. Risks before
and after a SBP reduction are estimated using the Framingham
cardiovascular risk equation for a hypothetical population of
hypertensives. Improved 24-hour ABP confers additional risk
reduction, while non-compliance mitigates the reduction depend-
ing on each ARB’s duration of effect. Drug costs are based on
wholesale acquisition cost and average dosing from IMS national
estimates for 2003. RESULTS: Over a 5-year timeframe in a rep-
resentative hypertensive population, ARBs reduce cardiovascu-
lar events by 15% to 25% at a yearly cost of $185 to $301 per
treated patient or $34,914 to $90,487 per event avoided. The
NNT to avoid one event varies from 37.6 for telmisartan to 62.2
for valsartan. Over 5-years, relative to telmisartan, the model
predicts 547 (olmesartan) to 1052 (valsartan) more cardiovas-
cular events per 100,000 hypertensive patients. Telmisartan gen-
erates cost savings relative to all ARBs. Assuming no difference
between ARBs in cuff SBP reduction, the effects of ABP and non-
compliance alone favor telmisartan by 398 to 696 events. The
model is sensitive to factors that substantially impact cardiovas-
cular risk like patient age and is more sensitive to ABP differ-
ences than to noncompliance. CONCLUSION: Small differences
in SBP reduction between ARBs may produce meaningful dif-
ferences in the number of cardiovascular events avoided. Telmis-
artan’s smooth ABP proﬁle and reduced consequences from
non-compliance relative to other ARBs enhance its effectiveness.
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COST EFFECTIVENESS ANALYSIS OF THERAPY
MODIFICATION AFTER FAILING STATIN TREATMENT
Grauer DW1, Franic DM2, Sullins G1
1The University of Kansas, Kansas City, KS, USA; 2The University of
Georgia, Athens, GA, USA
OBJECTIVE: A literature search revealed a lack of information
on how to treat patients who have failed to meet goal LDL level
on statin therapy. The purpose of this retrospective, cohort study
was to compare the cost-effectiveness of increasing the statin
dose, changing to a different statin, adding an alternative therapy
to the statin, changing to a different therapy, or not making any
changes. METHODS: Medical charts of patients (n = 64) in a
lipid clinic were utilized to gather patient demographics, CHD
risk factors, treatment history, and laboratory values. Effective-
ness was measured by whether the patient met goal LDL levels.
Intervention costs included the cost of the medications, physi-
cian visits, and laboratory tests. RESULTS: The lowest total
average cost occurred when the statin was changed to an alter-
native therapy ($96.39), followed by changing to a different
statin ($131.40), increasing the statin dose ($134.69), making no
change in therapy ($137.95), and adding an additional therapy
to the statin ($153.03). The probability of a patient meeting LDL
